Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 96,400 shares, a growth of 62.3% from the January 31st total of 59,400 shares. Based on an average daily trading volume, of 41,300 shares, the short-interest ratio is presently 2.3 days. Currently, 0.4% of the shares of the stock are sold short.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 target price on shares of Elutia in a report on Friday, November 15th.
Read Our Latest Stock Analysis on Elutia
Elutia Trading Down 5.7 %
Institutional Trading of Elutia
Several large investors have recently added to or reduced their stakes in ELUT. Perkins Capital Management Inc. boosted its position in shares of Elutia by 9.8% in the third quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock worth $3,263,000 after buying an additional 76,450 shares during the period. Arcus Capital Partners LLC grew its holdings in shares of Elutia by 100.0% during the third quarter. Arcus Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $76,000 after buying an additional 10,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Elutia by 50.3% during the third quarter. Geode Capital Management LLC now owns 188,408 shares of the company’s stock valued at $718,000 after buying an additional 63,047 shares in the last quarter. AIGH Capital Management LLC grew its holdings in shares of Elutia by 22.5% during the fourth quarter. AIGH Capital Management LLC now owns 3,074,675 shares of the company’s stock valued at $11,499,000 after buying an additional 564,233 shares in the last quarter. Finally, Silverarc Capital Management LLC grew its holdings in shares of Elutia by 8.3% during the fourth quarter. Silverarc Capital Management LLC now owns 1,782,271 shares of the company’s stock valued at $6,666,000 after buying an additional 136,463 shares in the last quarter. 74.03% of the stock is owned by institutional investors and hedge funds.
Elutia Company Profile
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Recommended Stories
- Five stocks we like better than Elutia
- What Are Treasury Bonds?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Dividend Capture Strategy: What You Need to Know
- Tesla Stock: Finding a Bottom May Take Time
- Manufacturing Stocks Investing
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.